Ozempic: GLP-1 analogues may reduce the risk of several obesity-related cancers
In addition to their effects on type 2 diabetes, weight loss and colorectal cancer risk, glucagon-like peptide-1 receptor analogues may also act on nine other obesity-related cancers, reports a new study.